BRIEF published on 12/04/2025 at 07:35, 9 months 14 days ago ADOCIA Secures €10 Million Fundraising for Growth Shares Fundraising Investment Biopharmaceutical ADOCIA
PRESS RELEASE published on 12/04/2025 at 07:30, 9 months 14 days ago Inside Information / Other news releases Adocia successfully completes a €10 million fundraising through a capital increase. Proceeds to support technology platform development. Cash runway extended to 2027 Fundraising Capital Increase Cash Runway ADOCIA Technology Platforms
BRIEF published on 11/12/2025 at 07:35, 10 months 6 days ago Adocia Progresse with AdoXLongTM and BioChaperone® Diabetes Patent ADOCIA BioChaperone® AdoXLongTM
PRESS RELEASE published on 11/12/2025 at 07:30, 10 months 6 days ago Inside Information / Other news releases Adocia files patent for AdoXLongTM platform to extend duration of action for peptides in diabetes and obesity treatment. BioChaperone® platform updated with feasibility studies Obesity Treatment Diabetes Treatment Patent Filing ADOCIA AdoXLongTM
BRIEF published on 10/21/2025 at 10:47, 10 months 28 days ago Crossing thresholds at ADOCIA Warrants Actions Crossing Thresholds ADOCIA Vester Finance
BRIEF published on 10/15/2025 at 08:50, 11 months 3 days ago Positive results for BioChaperone® Lispro insulin in Phase 3 Clinical Trial Type 1 Diabetes ADOCIA BioChaperone® Tonghua Dongbao
PRESS RELEASE published on 10/15/2025 at 08:45, 11 months 3 days ago Inside Information / Other news releases ADOCIA and Tonghua Dongbao announce positive Phase 3 results for Ultra-Rapid Insulin BioChaperone Lispro in Type 1 Diabetes treatment, showing non-inferior HbA1c reduction and improved blood glucose control post-meal Type 1 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
BRIEF published on 07/25/2025 at 08:50, 1 year 1 month ago Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin Diabetes Treatment Clinical Trial Phase 3 Results ADOCIA BioChaperone® Lispro
PRESS RELEASE published on 07/25/2025 at 08:45, 1 year 1 month ago Inside Information / Other news releases Adocia and Tonghua Dongbao announce positive Phase 3 results of Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in Type 2 Diabetes. Significant HbA1c reduction and improved post-meal blood glucose levels compared to Humalog® Type 2 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
BRIEF published on 04/04/2025 at 11:21, 1 year 5 months ago Vester Finance reduces its stake in ADOCIA Voting Rights Actions Threshold Crossing ADOCIA Vester Finance
Published on 09/18/2026 at 13:30, 36 minutes ago Alset AI Provides Shareholder Update, Announces Updated Investor Presentation and Appoints Mitchell Jackman as Chief Financial Officer
Published on 09/18/2026 at 06:30, 7 hours 36 minutes ago GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling
Published on 09/18/2026 at 00:55, 13 hours 11 minutes ago Tectonic Metals Announces Results of the 2026 Annual General Meeting
Published on 09/18/2026 at 00:25, 13 hours 41 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/18/2026 at 13:52, 14 minutes ago New rules for green claims. Does eco-friendly also mean animal-friendly?
Published on 09/18/2026 at 13:51, 14 minutes ago Completion of the Acquisition of a Majority Stake in Jucari Global Pty Ltd
Published on 09/18/2026 at 13:50, 16 minutes ago Omio expands premium overnight travel options with Twiliner
Published on 09/18/2026 at 13:30, 36 minutes ago EQS-Adhoc: Sibanye Gold Limited: Notice to Bondholders
Published on 09/18/2026 at 13:30, 36 minutes ago EQS-Adhoc: Avemio AG: Preliminary Revenue and Earnings Figures for Fiscal Year 2025
Published on 09/17/2026 at 17:40, 20 hours 26 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 20 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 2 days 7 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
